Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses

• Published in: PloS one Vol. 11; no. 6; p. e0157129
• Main Authors: Li, Xue, Tse, Vicki C, Lau, Wallis C Y, Cheung, Bernard M Y, Lip, Gregory Y H, Wong, Ian C K, Chan, Esther W
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 30.06.2016; Public Library of Science (PLoS)
• Subjects: Aged; Aged, 80 and over; Analysis; Anticoagulants; Anticoagulants - economics; Anticoagulants - therapeutic use; Atrial fibrillation; Atrial Fibrillation - drug therapy; Atrial Fibrillation - economics; Bleeding; Computer simulation; Cost analysis; Cost benefit analysis; Databases, Factual; Demographics; Demography; Disease Progression; Economic aspects; Female; Fibrillation; Health aspects; Health care; Health Care Costs; Health risk assessment; Hong Kong; Humans; Male; Markov chains; Markov processes; Medical electronics; Medical research; Medicine and Health Sciences; Models, Theoretical; Mortality; Patients; People and places; Prophylaxis; Pyrazoles - economics; Pyrazoles - therapeutic use; Pyridones - economics; Pyridones - therapeutic use; Quality-Adjusted Life Years; Retrospective Studies; Sensitivity analysis; Social Sciences; Statistical analysis; Stroke; Stroke - economics; Stroke - prevention & control; Systematic review; Thromboembolism; Warfarin; Warfarin - economics; Warfarin - therapeutic use; United Kingdom > UK; Hong Kong China; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0157129

Many of the cost-effectiveness analyses of apixaban against warfarin focused on Western populations but Asian evidence remains less clear. The present study aims to evaluate the cost-effectiveness of apixaban against warfarin in Chinese patients with non-valvular atrial fibrillation (NVAF) from a public institutional perspective in Hong Kong. We used a Markov model incorporating 12 health state transitions, and simulated the disease progression of NVAF in 1,000 hypothetical patients treated with apixaban/warfarin. Risks of clinical events were based on the ARISTOTLE trial and were adjusted with local International Normalized Ratio control, defined as the time in therapeutic range. Real-life input for the model, including patients' demographics and clinical profiles, post-event treatment patterns, and healthcare costs, were determined by a retrospective cohort of 40,569 incident patients retrieved from a Hong Kong-wide electronic medical database. Main outcome measurements included numbers of thromboembolic and bleeding events, life years, quality-adjusted life years (QALYs) and direct healthcare cost. When comparing apixaban and warfarin, treatment with incremental cost-effectiveness ratio (ICER) less than one local GDP per capita (USD 33,534 in 2014) was defined to be cost-effective. In the lifetime simulation, fewer numbers of events were estimated for the apixaban group, resulting in reduced event-related direct medical costs. The estimated ICER of apixaban was USD 7,057 per QALY at base-case analysis and ranged from USD 1,061 to 14,867 per QALY under the 116 tested scenarios in deterministic sensitivity analysis. While in probabilistic sensitivity analysis, the probability of apixaban being the cost-effective alternative to warfarin was 96% and 98% at a willingness to pay threshold of USD 33,534 and 100,602 per QALY, respectively. Apixaban is likely to be a cost-effective alternative to warfarin for stroke prophylaxis in Chinese patients with NVAF in Hong Kong.